Classement en actions
#11212
EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating... EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating therapies, predominantly for oncological (cancer) and immune-inflammatory conditions. The company's late-stage pipeline features two promising drug candidates in Phase III clinical trials: Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor specifically for patients with EGFR-mutated non-small cell lung cancer (NSCLC), and Sugemalimab, an anti-programmed death-ligand 1 antibody aimed at treating Stage III and Stage IV NSCLC. Its broader developmental portfolio encompasses a range of additional clinical and pre-clinical assets. This portfolio includes Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor in Phase II trials for metastatic breast cancer; EQ176, an anti-programmed death-1 antibody undergoing Phase III development for primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor currently in various Phase I studies. Established in 2019, EQRx maintains its corporate headquarters in Cambridge, Massachusetts.
Prix de l'action
$2.34
Dernière synchronisation: 2023-11-09
Capitalisation boursière
$728.90M
Changement (1 jour)
0.00%
Échange EQRx, Inc. (EQRX)
Le prix EQRX avec la capitalisation boursière de B
Capitalisation boursière de EQRx, Inc.(EQRX)
Capitalisation boursière: $728.90M
En August 2026, EQRx, Inc. a une capitalisation boursière de $728.90M. Cela fait de EQRx, Inc. la 11212th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de EQRx, Inc. du 2021 au 2026
EQRX par rapport au top 5 des plus populaires stocks
| Prix pour EQRX |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.264T
|
+722,063.20%
|
|
|
|
|
$4.701T
|
+644,879.82%
|
|
|
|
|
$4.177T
|
+572,977.48%
|
|
|
|
|
$3.817T
|
+523,618.82%
|
|
|
|
|
$2.866T
|
+393,139.94%
|
